Drug news
Crestor US patent to expire- AstraZeneza
The US patent for Crestor (rosuvastatin) will expire next week which will affect one fifth of AstraZeneca sales. Crestor sales for the year ended 2015 were around $5 billion and are expected to drop dramatically as generics enter the market as happened with its predecessor Lipitor from Pfizer. AstraZeneca are planning an internal restructuring and plan to target sales and administrative functions.
On 29 April the FDA has approved the first generic rosuvastatin for Watson Pharma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.